Sandoz Group stock
Price history
+52.66% over the period1 year: from CHF 54.92 (November 17, 2025) to CHF 83.84 (November 17, 2026), +52.66%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | CHF 83.84 |
| October 30, 2026 | CHF 82.38 |
| September 30, 2026 | CHF 70.86 |
| August 31, 2026 | CHF 67.92 |
| July 31, 2026 | CHF 65.76 |
| June 30, 2026 | CHF 73.12 |
| May 29, 2026 | CHF 65.60 |
| April 30, 2026 | CHF 62.54 |
| March 31, 2026 | CHF 61.74 |
| February 27, 2026 | CHF 68.02 |
| January 30, 2026 | CHF 61.18 |
| December 30, 2025 | CHF 57.84 |
| November 28, 2025 | CHF 56.72 |
| November 17, 2025 | CHF 54.92 |
At a glance
The company
Develops, manufactures and markets generic drugs and biosimilars for multiple therapeutic areas worldwide
Latest results
Quarter to June 30, 2026 · EPS $0.25
Next event
TickerLandia's take on Sandoz Group
- Pricier than similar companies: trailing 12-month P/E 72 vs 25 (+190%) in a group of 11.
- Strong point: Market momentum (82/100 in its group). Weak point: Profitability (18/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.49% from the 52-week high
Analysts · 16 analysts
Average targetCHF 81.53−1.77% vs. price
Buy 7 · Hold 7 · Sell 2 · Buy
TickerLandia Fingerprint: Sandoz Group
Compared with similar companies: very strong momentum and very low profitability.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricehigh67
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 72.3 84 Forward P/E 22.0 53 EV/EBITDA 26.0 76 Price/sales 3.14 50 Price/book 4.96 72 Profitabilityvery low18
How much it earns on revenue and capital.
Metric Value Position in group ROE 7.2% 22 Operating margin 9.3% 14 Gross margin 47.8% 17 Net margin 5.5% 20 ROA 3.0% 17 Earnings stabilityaverage45
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.7% 28 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthlow33
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +6.23% 43 Earnings growth (year over year) −71.30% 13 Revenue growth (year over year) +9.90% 42 Financial strengthlow22
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 6.57 24 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.09 26 Debt/equitycounts in reverse: lower means more financial strength 0.69 24 Current ratio 1.05 14 Dividendaverage46
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 3 years 14 Dividend yield 0.9% 35 Payout ratio 68.4% 88 Market momentumvery strong82
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +5.53% 69 Relative strength (6 months) +11.57% 78 1-year return +51.13% 89 Distance from 200-day average +20.82% 92 Riskaverage50
How much the price swings.
Metric Value Position in group Beta (1 year) 1.05 74 Volatility (60 days) 27.8% 52 Maximum drawdown (12 months) 17.6% 24
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Sandoz Group is pricier than similar companies
Sandoz Group's P/E (trailing 12 months): 72.3, +190% against the median of a group of 11 similar companies (25.0).
Compared with 11 similar companies
| Metric | Sandoz Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 72.3 | High | |
| Forward P/E | 22.0 | High | |
| Operating margin | 9.3% | Low | |
| ROE | 7.2% | Low | |
| Debt/equity | 0.69 | High |
Grey band: the middle half of the group; tick: the median; dot: Sandoz Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$5.78B
Latest quarter · Q2 2026
Net income
$109M
Latest quarter · Q2 2026
Quarterly net margin
1.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 36.61B
- P/E
- 72.3
- EPS
- CHF 1.17
- Volume
- 884.65K
- Daily trading
- €99.78M
- Dividend yield
- 0.96%
- Last ex-dividend on April 13, 2026
How Sandoz Group is changing
All resultsRevenue grew 2.9% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 136% of net income
Revenue has grown for 3 fiscal years in a row
Returns
Sandoz Group returns with dividends
CHF 1,000 invested in Sandoz Group 3 years ago, on November 17, 2023, would be worth CHF 3,433 today with dividends reinvested: +243.28% in total, +50.84% per year. On price alone it would be CHF 3,283 (+228.27%).
| Period | Sandoz Group | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | +9.48% | +4.53% | CHF 1,095 |
| 6 months | +26.76% | +13.61% | CHF 1,268 |
| Year to date | +44.95% | +13.20% | CHF 1,450 |
| 1 year | +54.51% | +19.22% | CHF 1,545 |
| 3 years | +243.28% | +39.88% | CHF 3,433 |
Over the last 6 months it has done better than 42% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Sandoz Group: technical analysis
Sandoz Group is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.5% below its all-time closing high (CHF 86.90, November 12, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 57
- Between 30 and 70
- vs 200-session average
- +20.82%
Support and resistance
Price areas where Sandoz Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last priceCHF 83.00
- SupportCHF 75.37−9.19%3 touches, last on October 28, 2026
- SupportCHF 72.20−13.01%2 touches, last on September 8, 2026
- SupportCHF 68.67−17.27%2 touches, last on May 13, 2026
Volatility and risk
Over the last year it has moved roughly in line with the SMI.
- Beta (1 year) vs SMI
- 1.05
- Volatility (60 sessions, annualised)
- 27.8%
- Largest fall in the last year
- −17.62%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
The company
Sandoz Group and its competitors
Sold worldwide, the generic and biosimilar medicines of Sandoz Group AG are developed, manufactured and marketed by the company across a wide range of therapeutic areas, including oncology, cardiovascular and central nervous system disorders, immunology, diabetes and ophthalmology. Its therapeutic coverage also extends to hematology, nephrology, neurology and endocrinology. Its offering includes active pharmaceutical ingredients and finished dosage forms. A strategic collaboration with Shanghai Henlius Biotech aims to broaden patient access to biosimilar medicines.
- Headquarters
- Basel, Switzerland
- Employees
- 20,000
- Founded
- 1886
- Chief executive
- Richard Saynor
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Sandoz GroupSDZ | $43.57B | 9.3% | 72.3 | +26.76% |
| HaleonHLN | $40.15B | 23.5% | 19.3 | +2.82% |
| Galderma GroupGALD | $51.94B | 19.1% | 64.5 | +19.47% |
| MerckMRK | $71.52B | 17.0% | 33.9 | +28.46% |
| Swedish Orphan BiovitrumSOBI | $16.27B | 30.9% | 25.0 | +7.21% |
| IpsenIPN | $14.2B | 27.4% | 25.5 | −1.14% |
Same industry or related industries, similar size. Compare Sandoz Group with its competitors · Full profile
